title: Obese men respond to cognitive but not to catabolic brain insulin signaling.
abstract: OBJECTIVE
  Insulin acts in the brain to reduce food intake and body weight and is considered a major adiposity signal in energy homeostasis. In normal-weight men, intranasal insulin administration reduces body fat and improves declarative memory. The present experiments aimed to generalize these findings to obese patients, with a view to evaluate the therapeutic potential of the compound.
  
  
  METHODS
  Insulin and placebo, respectively, were intranasally administered four times a day (amounting to 160 IU day(-1)) over 8 weeks to two groups of 15 obese men each.
  
  
  RESULTS
  Contrasting with the catabolic effects in normal-weight men, insulin treatment did not induce any significant reduction of body weight (P>0.50) and body fat (P>0.44) in the obese subjects. However, in accordance with the effects in normal-weight men, declarative memory and mood were improved (P<0.05) and hypothalamic-pituitary-adrenal axis activity as assessed by circulating ACTH (P<0.01) and cortisol levels (P<0.04) was reduced.
  
  
  CONCLUSIONS
  Our results indicate that in obese men, intranasal insulin is functionally active in the central nervous system but fails to affect the neuronal networks critically involved in body weight regulation. We conclude that obesity in men is associated with central nervous resistance to the adiposity signal insulin. This defect likely contributes to the persistence of obesity in spite of elevated levels of circulating insulin in obese patients.
authors.affiliation: Department of Neuroendocrinology, University of Lübeck, Lübeck, Germany. hallschmid@kfg.uni-luebeck.de
authors.forename: M
authors.initials: M
authors.lastname: Hallschmid
authors.forename: C
authors.initials: C
authors.lastname: Benedict
authors.forename: B
authors.initials: B
authors.lastname: Schultes
authors.forename: J
authors.initials: J
authors.lastname: Born
authors.forename: W
authors.initials: W
authors.lastname: Kern
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects*; D000281:Administration, Intranasal; D000328:Adult; D000339:Affect / Q000187:drug effects; D049628:Body Size; D001835:Body Weight; D001921:Brain / Q000187:drug effects*; D003071:Cognition / Q000187:drug effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008568:Memory / Q000187:drug effects*; D009765:Obesity / Q000523:psychology*; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin